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CytotoxicityAbstract Two proline containing cyclic dipeptides (CDPs), cyclo (L-Pro-L-Tyr) (1) and cyclo
(L-Pro-L-Phe) (2) were isolated from the fermentation broth of Pseudonocardia endophytica VUK-
10 originating from the Nizampatnam mangrove ecosystem on the south coast of Andhra Pradesh,
India. The structures of the compounds were established by 1H NMR and 13C NMR spectroscopy,
FTIR and EIMS. The antimicrobial and cytotoxic activities of the compounds were tested against a
variety of medicinally and agriculturally important bacteria and fungi as well as on the MDA-MB-
231, OAW-42, HeLa and MCF-7 human cell lines. Xanthomonas malvacearum was most sensitive
toward 1 (MIC 4 lg/ml), whereas compound 2 had good antibacterial activity against Xanthomonas
campestris (MIC 8 lg/ml). Fusarium solani was highly sensitive toward 1 (MIC 16 lg/ml). The com-
pounds were cytotoxic against the human cell lines at micro molar concentrations; the highest activity
(IC50 < 10 lM) of 1 was recorded against the MDA-MB-231 cancer cell line.
 2016 Production and hosting by Elsevier B.V. on behalf of Academy of Scientific Research &
Technology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Effective novel drugs are in great demand to restrain the
spread of antibiotic-resistant pathogens. Natural products
and their derivatives are invaluable sources of therapeutic
agents. Their multitude, chemical diversity and complexityconfer potent biological activities that allow the discovery of
new drugs for the control and treatment of human illnesses
[1–4]. Actinobacteria are a valuable source of bioactive natural
products, and great efforts are made to search undisturbed
natural habitats for such microorganisms to enhance the dis-
covery of novel bioactive metabolites [5,6]. Soils of such
sources have been widely exploited, but there are only few
and inconclusive investigations of actinobacteria from man-
grove sediment available, even though they are reliable sources
for the discovery of new bioactive compounds [7,8]. In recent
years, there has been a growing awareness of the value of man-
grove sediments as sources of actinobacteria.
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the highest economical and biotechnological potential, as they
produce a wide range of promising bioactive secondary com-
pounds including antibiotics, antitumor agents, immune sup-
pressive drugs and enzymes. The genus Pseudonocardia
belongs to the order Actinomycetales, members of which are
well known for their proven ability to produce bioactive
metabolites and other molecules of pharmaceutical interest,
but relatively few natural products have been described from
species of this particular genus [9]. Antibiotics discovered from
Pseudonocardia spp. include deoxyniboquinone, three diazaan-
thraquinone derivatives, the pseudonocardians A-C [10], den-
tigerumycin [11], phenazostatin D [12], and the polyketide
NPP [13]. Of these, deoxyniboquinone, the pseudonocardians
A-C and phenazostatin D are produced by marine Pseudono-
cardia spp. isolated from deep sea sediment of the South China
Sea and the littoral of Mauritius (Indian Ocean), respectively.
They have potent antimicrobial, cytotoxic and neuroprotective
properties. Dentigerumycin is a cyclic depsipeptide that was
isolated from a Pseudonocardia sp. associated with a fungus
growing in the ant Apterostigma dentigerum and NPP is an
antifungal polyketide produced by the soil actinomycete
Pseudonocardia autotrophica KCTC 9441. Based on the above
description, the genus Pseudonocardia have been proved as the
best dependable resource for active metabolites, though the
genus was less explored for natural products.
In the course for the search of bioactive metabolites, the
morphologically distinct actinobacterial strain VUK-10, hav-
ing good antimicrobial potential, was selected from 55 acti-
nobacterial strains isolated from sediment samples of the
Nizampatnam mangrove ecosystem (Andhra Pradesh, India).
The strain VUK-10 was classified as Pseudonocardia endophyt-
ica (JN087501) by polyphasic taxonomy [14]. Two bioactive
compounds, 4-(2-acetamidoethyl) phenyl acetate and 4-((1,4-
dioxooctahydropyrrolo [1,2-a] pyrazin-3-yl) methyl) phenyl
acetate with potent anti-microbial and cytotoxic activities were
reported from this strain [15]. In the ongoing research, we
report here the isolation, structural elucidation and biological
evaluation of two further bioactive compounds from
Pseudonocardia endophytica VUK-10.2. Materials and methods
2.1. Fermentation, isolation and identification of metabolites
A seed culture of Pseudonocardia endophytica VUK-10 was
grown in YMD broth (seed broth) and incubated on a rotary
shaker (250 rpm) at 35 C for 48 h. Seed culture at concentra-
tion of 10% (100 ml of the seed culture in 1000 ml of the produc-
tion medium) was transferred into the optimized fermentation
medium (glucose [1%, w/v], tryptone [0.5%], K2HPO4
[0.05%], NaCl [3%] and FeSO4 [0.001%]; pH adjusted to 7.0)
[16]. After cultivation of the strain for 96 h, the culture filtrates
(50 L) were extracted twice with ethyl acetate, the extract con-
centrated by rotary evaporation and then freeze-dried to yield
7.6 g of a dark brown residue of the crude extract.
The ethyl acetate crude extract was subjected to Sephadex
LH-20 gel filtration chromatography using dichloromethane/
methanol (1:1, v/v) as eluent, resulting in yielding nine
fractions. Based on the 1H NMR spectral data and bioassay,
fraction VII (3.34 g) was selected for further studies andsubjected to silica gel column chromatography (25  5 cm, Sil-
ica gel 60, Merck) which afforded fractions 1–5. Based on TLC
monitoring, NMR spectral data and antibacterial activity
against B. subtilis, sub fractions 1 (294 mg) and 3 (340 mg)
were selected for further purification by silica gel column chro-
matography (22  5 cm, Silica gel 100, Merck) using n-hexane/
isopropanol (95:5) and dichloromethane/ethyl acetate/acetone
(2:1:1), which yielded compound 1 (32 mg) and 2 (22 mg),
respectively. The structures of 1 and 2 were elucidated by
nuclear magnetic resonance (Avance 300 MHz) (1H and 13C
NMR; model: Varian Gemini 200 and samples were made in
CCL4/CDCL3 + DMSO using tetra methyl silane as internal
standard; NMR Spectroscopy Division IICT-Hyderabad)
spectroscopy, EIMS (Electron ionization mass; model:
micromass VG-7070H, 70 eV spectrophotometer; Mass
Spectroscopy Division IICT-Hyderabad) and FTIR (Fourier
transform infra-red; Thermo Nicolet Nexus 670 spectropho-
tometer with NaCl optics).
2.2. Test micro organisms
Gram positive bacteria: Bacillus cereus (MTCC 430), Strepto-
coccus mutans (MTCC 497), Staphylococcus aureus (MTCC
3160), Staphylococcus epidermis (MTCC 120), Bacillus subtilis
(ATCC 6633), Bacillus megaterium (NCIM 2187); Gram nega-
tive bacteria: Escherichia coli (ATCC 35218), Pseudomonas
aeruginosa (ATCC 9027), Proteus vulgaris (MTCC 7299), Ser-
ratia marcescens (MTCC 118) Xanthomonas campestris
(MTCC 2286), Xanthomonas malvacearum (NCIM 2954) and
Salmonella typhi (ATCC 14028); medically important der-
matophytes: Candida albicans (ATCC 10231) and Epidermo-
phyton floccosum (MTCC 145); medically and agriculturally
important filamentous fungi: Aspergillus niger (ATCC 1015),
Aspergillus flavus (ATCC 9643), Fusarium oxysporum (MTCC
3075), Fusarium solani (MTCC 4634), Penicillium citrinum
(MTCC 6489), Verticillium alboatrum and Alternaria alternata
(MTCC 6572). The test microorganisms were procured from
ATCC, Manassas, VA, USA, and MTCC, Chandigarh,
NCIM, Pune, India, and preserved at 4 C.
2.3. MIC assay
Minimum inhibitory concentrations (MIC) of the test com-
pounds against bacteria and fungi were determined in an agar
plate diffusion assay [17] in triplicates for each concentration.
Mueller–Hinton agar and Czapek–Dox agar media were pre-
pared to grow the bacteria and fungi, respectively. The purified
compounds were dissolved in dimethyl sulfoxide at concentra-
tions ranging from 0 to 1000 lg/ml. The inoculated plates were
examined after 24–48 h of incubation at 37 C for bacteria and
48–72 h at 28 C for fungi. The lowest concentration of the
compounds exhibiting significant antimicrobial activity against
the test micro organisms was taken as the MIC of the com-
pound. The standard antibiotics used in this study were Tetra-
cycline against bacteria, Griseofulvin against dermatophytes
and Amphotericin-B against fungi.
2.4. MTT assay
The cytotoxicity of the compounds against human cancer cell
lines was assessed in 96 well plates by measuring the reduction
Figure 1 Molecular structures of 3-(4-hydroxy benzyl) hexahy-
dropyrrolo [1,2-a] pyrazine-1,4-dione and 3-benzyl hexahydropy-
rrolo [1,2-a] pyrazine-1,4-dione.
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mide (MTT) to the water insoluble formazan crystals [18].
The cell lines were human breast adenocarcinoma (MDA-
MB-231) (cell line reported to be resistant to cancer drugs)
[19], human cervical cancer (HeLa), human ovarian cyst ade-
nocarcinoma (OAW-42) and human breast adenocarcinoma
(MCF-7) cell lines that had been obtained from the National
Centre for Cell Science, Pune, India. The cell lines MDA-
MB-231, HeLa and OAW-42 were cultivated in Dulbecco’s
modified Eagle’s medium supplemented with fetal bovine
serum (10%; v/v), L-glutamine (2 mM), penicillin (10 units/
ml) and streptomycin (10 lg/ml), while the MCF-7 cell line
was cultivated in Roswell Park Memorial Institute medium
1640 with the same supplements, all in a humidified atmo-
sphere (95%) with 5% of CO2 at 37 C. Cells were seeded in
96-well microtiter plates at a density of 5  103 per well con-
taining 100 ll medium. After overnight incubation, the test
compounds were added at 10, 100, 1000 and 5000 nM concen-
trations, each in triplicate. After 24 h of further incubation,
cell viability was assessed by adding 20 ll of MTT (5 mg/ml
in PBS) per well, and the plates were incubated at 37 C for
4 h. The formazan crystals formed in the cells were dissolved
by addition of 100 ll of 0.1% acidified isopropanol, and the
optical density was measured at 570 nm using a micro plate
reader. The IC50 values (50% inhibitory concentration) of
the compounds were calculated using Sigma Plot software with
reference to that of taxol as standard. All the experiments were
carried out in triplicate.
3. Results
3.1. Fermentation, isolation and identification of metabolites
Culture filtrates obtained after 96 h fermentation of Pseudono-
cardia endophytica VUK-10 were extracted with ethyl acetate
and concentrated to yield a dark brown residue, which in turn
was subjected to gel filtration chromatography using the sol-
vent system of dichloromethane/methanol. Among the nine
fractions collected, fraction VII exhibiting good antimicrobial
activity was rechromatographed on a silica gel column and
yielded 5 fractions. Further purification of active sub fractions
1 and 3 by sequential chromatographic purifications on silica
gel yielded the two antimicrobial compounds 1 and 2.
Compound (1) was obtained as white amorphous powder,
wholly soluble in dimethyl sulfoxide, methanol, ethanol and
chloroform, [a]D
25-87.1 (c0.8, MeOH). The 1H NMR spectrum
of compound showed signals at d 7.04 (d, 2H, J= 8.49 Hz);
6.78 (d, 2H, J= 8.49 Hz); 6.57 (bs, 1H); 5.8 (s, 1H); 4.22
(dd, 1H, J= 2.83, 10.19 Hz); 4.08 (t, 1H, J= 7.17 Hz);
3.69–3.44 (m,3H); 2.74 (dd, 1H, J= 10.19, 14.54 Hz); 2.37–
2.27 (m,1H); 2.05–1.84 (m,3H) (see Supplementary Material,
Fig. 1); while 13C exhibited 12 signals at d 169.691; 165.243;
155.81; 130.34; 126.59; 116.008; 59.06; 56.27; 45.34; 35.93;
28.26 and 22.32 (see Supplementary Material, Fig. 2). EIMS
analysis of the compound gave a molecular ion m/z at 283
(M+Na) (see Supplementary Material, Fig. 3). The IR spec-
trum exhibited absorption bands at Vmax 3243, 2961, 1662,
1514, 1445, 1261, 800 cm1 (see Supplementary Material,
Fig. 4). Based on the above spectral data, the compound 1
was identified as (3S, 8aS)-3-(4-hydroxybenzyl) hexahydropy-
rrolo [1,2-a] pyrazine-1,4-dione [Cyclo(L-Pro-L-Tyr)], with
the molecular formula of C14H16N2O3 (Fig. 1A).Compound (2) was obtained as a white solid, freely soluble
in dimethylsulfoxide, methanol, ethanol and chloroform, [a]D
25-
93.4 (c 1.1, MeOH). The 1H NMR spectrum of the compound
showed signals at d 7.30 (m,5H); 5.70 (s, 1H); 4.28 (dd, 1H,
J= 2.83, 10.38 Hz); 4.07 (t, 1H, J= 6.79 Hz); 3.69–3.52
(m,3H); 2.77 (dd, 1H, J= 10.38, 14.35 Hz); 2.39–2.29
(m,1H); 2.08–1.80 (m,3H) (see Supplementary Material,
Fig. 5); while 13C exhibited 12 signals at d 166.3; 165.1;
135.8; 129.1 (2C); 129.0 (2C); 127.3; 59.0; 56.2; 45.3; 36.6;
28.2 and 22.3 (see Supplementary Material, Fig. 6). EIMS
analysis of the compound gave a molecular ion m/z at 245
(M+H) and 267 (M+ Na) (see Supplementary Material,
Fig. 7). The IR spectrum displayed absorption bands at Vmax
3257, 2927, 1665, 1436, 1219 and 755 cm1 (see Supplementary
Material, Fig. 8). Based on the supra mentioned spectral data,
the compound 2 was identified as 3-benzyl hexahydropyrrolo
[1,2-a] pyrazine-1,4-dione [Cyclo(L-Pro-L-Phe)], with the
molecular formula of C14H16N2O2 (Fig. 1B).
3.2. Biological assays
3.2.1. MIC assay of antibacterial and antifungal activities
MIC assay. Antibacterial activities of the bioactive compounds
(1 and 2) in terms of MIC are shown in Table 1. The bioactive
compounds exhibited antibacterial activity against a variety of
gram-positive and gram-negative bacteria, for which the MIC
values ranged from 4 to 128 lg/ml. Among the opportunistic
and pathogenic bacteria, compound 1 was active against all
the bacteria tested, and the best activity of this compound
was recorded against Xanthomonas malvacearum (4 lg/ml), fol-
lowed by Staphylococcus aureus and Escherichia coli (8 lg/ml).
Compound 2 presented the highest sensitivity to Xanthomonas
campestris (8 lg/ml) followed by Streptococcus mutans and
Pseudomonas aeruginosa (16 lg/ml). Tetracycline served as
the positive control for bacteria. Compared with the standard
drug tetracycline, compound 1 displayed high sensitivity
against Xanthomonas malvacearum and Staphylococcus aureus
and 2 against Xanthomonas campestris, Streptococcus mutans
while in some cases compound 1 (Escherichia coli) & 2
(Staphylococcus aureus) recorded similar sensitivity like posi-
tive control (Table 1). Tetracycline, in other cases showed
good antibacterial activity over the metabolites of the strain.
Antifungal activities of the bioactive compounds against
dermatophytes and filamentous fungi and the corresponding
MIC values are recorded in Table 2. Compound 1 exhibited
significant MIC value against Candida albicans (16 lg/ml),
whereas compound 2 recorded activity at 32 lg/ml against
Epidermophyton floccosum. Among the filamentous fungi
tested, Fusarium solani recorded sensitivity of 16 lg/ml toward
Table 1 Minimum inhibitory concentrations (MIC, lg/ml) of compounds 1 and 2 produced by Pseudonocardia endophytica VUK-10
against gram positive and gram negative bacteria.
Test microorganisms 1a 2b Tetc
Staphylococcus aureus (MTCC 3160) 8 32 32
Streptococcus mutans (MTCC 497) 32 16 32
Staphylococcus epidermis (MTCC 120) 32 32 16
Xanthomonas campestris (MTCC 2286) 32 8 16
Xanthomonas malvacearum (NCIM 2954) 4 32 8
Bacillus subtilis (ATCC 6633) 64 64 32
Bacillus megaterium (NCIM 2187) 32 32 16
Bacillus cereus (MTCC 430) 64 64 8
Escherichia coli (ATCC 35218) 8 32 8
Pseudomonas aeruginosa (ATCC 9027) 64 16 8
Serratia marcescens (MTCC 118) 64 128 32
Proteus vulgaris (MTCC 7299) 128 128 16
Salmonella typhi (ATCC 14028) 64 64 8
a 1: Cyclo(L-Pro-L-Tyr).
b 2: Cyclo(L-Pro-L-Phe).
c Tet: tetracycline.
Table 2 Minimum inhibitory concentration (MIC, lg/ml) of compounds 1 and 2 produced by Pseudonocardia endophytica VUK-10
against dermatophytes and filamentous fungi.
Dermatophytes 1a 2b Antibioticc
Candida albicans (ATCC 10231) 8 64 16
Epidermophyton floccosum (MTCC 145) 64 32 16
Filamentous fungi
Aspergillus niger (ATCC 1015) 128 64 16
Aspergillus flavus (ATCC 9643) 64 128 8
Fusarium oxysporum (MTCC 3075) 32 32 16
Fusarium solani (MTCC 4634) 16 32 32
Penicillium citrinum (MTCC 6489) 64 64 8
Verticillium alboatrum (ATCC 13641) 512 NDd 64
Alternaria alternata (MTCC 6572) >512 256 32
a 1: Cyclo(L-Pro-L-Tyr).
b 2: Cyclo(L-Pro-L-Phe).
c Antibiotic: Griseofulvin against Yeast and Amphotericin-B against fungi.
d ND: not detected.
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ity up to 512 lg/ml. Compound 2 was active against Fusarium
solani and Fusarium oxysporum at 32 lg/ml, and for this com-
pound Verticillium alboatrum recorded no activity up to
1000 lg/ml. Compound 1 displayed high activity against
Fusarium solani compared to standard drug while in some
cases 1 (Candida albicans) and 2 (Fusarium solani) recorded
similar sensitivity like positive control (Table 2). In other cases
both compounds recorded lower antifungal activity than the
standard fungicides, Griseofulvin against dermatophytes and
Amphotericin-B against fungi.
3.2.2. MTT assay of cytotoxic activities
Compounds 1 and 2 were active against all four human cancer
cell lines tested (Figs. 2 and 3). Cell lines displaying IC50 values
of <10 lM (71.5%) (MDA-MB-231), <100 lM (71.3%,55%) (HeLa and MCF-7), <1000 lM (61.4%) (OAW-42)
for compound 1 (Fig. 2A–D).
The activity of compound 2 against MDA-MB-231, HeLa,
MCF-7 and OAW-42 cell lines is presented in Fig. 3A–D.
Compound 2 exhibited significant cytotoxicity with MDA-
MB-231, HeLa, MCF-7 and OAW-42 cell lines, exhibiting
IC50 values of <100 lM (59.6%, 69.1%) (MDA-MB-231,
HeLa) and <1000 lM (54%, 56.7%) (MCF-7, OAW-42).
Taxol, an anti-cancer drug used as the standard, recorded an
IC50 value of 10 lM (59%, 60%, 57% and 63%) against the
MDA-MB-231, HeLa, OAW-42 and MCF-7 cell lines.
4. Discussion
Diketopiperazines (DKPs), the smallest cyclic dipeptides
resulting from peptide bonds between two amino acids,
Figure 2 Growth of (A) MDB-MB-231, (B) HeLa, (C) MCF-7, (D) OAW-42 cancer cell lines as a function of the concentration of
compound 1.
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cal compounds. Due to their relatively simple and rigid struc-
ture, stability, chiral nature and varied side chains, DKPs have
been of research interest for their diverse bioactivities [20–22].
Some DKPs have diverse effects of pharmaceutical interest
including antibacterial [23], antifungal [24], antitumor [25],
antiviral [26], and anti-hyperglycemic [27] activities, as well
as other bioactivities including quorum-sensing signaling,
plant-growth promotion and inhibition of aflatoxin produc-
tion [28]. DKPs containing proline residues form the core of
several interesting natural product classes and exhibit promis-
ing bio-activities [29,30]. Therefore, diketopiperazines are priv-
ileged structures for the discovery of new lead compounds and
are also considered ideal for the rational development of new
therapeutic agents. In the present study, two compounds viz.,
3-(4-hydroxy benzyl) hexahydropyrrolo [1,2-a] pyrazine-1,4-
dione [cyclo (L-Pro-L-Tyr)] and 3-benzyl hexahydropyrrolo
[1,2-a] pyrazine-1,4-dione [cyclo (L-Pro-L-Phe)] active against
facultative and pathogenic bacteria, fungi and cancer cell lines,
were isolated from the culture broth of Pseudonocardia
endophytica.
Cyclo (L-Pro-L-Tyr) has been reported as a bioactive com-
pound from terrestrial and marine organisms including sea
urchin-derived Bacillus spp. [31], Streptomyces spp. TN256
strain [32], and sponge associated Pseudomonas aeruginosa
[33]. It has been reported to inhibit the growth of Saccha-
romyces cerevisiae by inhibiting family 18 chitinases [34]. A
MIC of 32 lg/ml was reported against Staphylococcus aureus[35], but we observed a somewhat greater potency against sim-
ilar bacteria with MIC values of 16 lg/ml. The isolation of
compound 2 was previously reported from Cladosporium phlei,
a pathogenic fungus of Phleum pratense [36] and from Bacillus
pumilus, a marine bacterium [37]. It exhibited antifungal activ-
ity against Aspergillus fumigatus and Penicillium roqueforti [38]
and antibacterial activity against B. subtilis, S. aureus, E. coli
and P. aeruginosa [35]. So far, the antimicrobial activity of
compounds 1 and 2 was reported only on few microorganisms.
We are providing here the first report of their antimicrobial
activity against medicinally and agriculturally important bac-
teria. Compound 1 is a good potential inhibitor against Xan-
thomonas malvacearum (causes angular leaf spot of cotton)
(4 lg/ml), Candida albicans (causes oral thrush and vaginal
infection) (16 lg/ml) and Fusarium solani (responsible for root
rot in beans), Fusarium (crown and foot rot of squash and
pumpkin, black rot of potato) (16 lg/ml). In our hands, 2
effectively inhibited growth of Xanthomonas campestris (causes
bacterial leaf spot on peppers and tomatoes) (8 lg/ml), Epider-
mophyton floccosum (causes tinea dermatophytoses), Fusarium
solani and Fusarium oxysporum (responsible for fusarium wilt,
fungal keratitis and onychomycosis) with an MIC of 32 lg/ml.
Cyclo (L-Pro-L-Tyr) and Cyclo (L-Pro-L-Phe) were known
compounds [39] and the spectral data of the both compounds
is quite agreement with the described literature. These two
compounds are previously reported for anti-cancer activity
against HeLa and MCF-7 cell lines [40]. In our study we
observed dependable potency against similar cell lines.
Figure 3 Growth of (A) MDB-MB-231, (B) HeLa, (C) MCF-7, (D) OAW-42 cancer cell lines as a function of the concentration of
compound 2.
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(71.3%; 69.1%) against HeLa, whereas 1 exhibited IC50 value
of <100 lM (55%) and 2 recorded IC50 value of <1000 lM
(54%) against MCF-7 cell lines. In addition, cytotoxic activity
of 1 and 2 against MDA-MB-231 and OAW-42 cell lines is
reported here for the first time. Both compounds showed good
inhibitory potentiality against all tested cell lines, with remark-
able display of activity against MDA-MB-231 (<10 lM) by
compound 1. The results of the present study show that the
compounds exhibit potent cytotoxic activities at impressively
low concentrations.
This is the first report of the isolation and characterization
of Cyclo (L-Pro-L-Tyr) (1) and Cyclo (L-Pro-L-Phe) (2) from
the genus Pseudonocardia.Acknowledgements
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